- Home
- ARKO vs RIGL Comparison
ARKO vs RIGL Comparison
Compare ARKO & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARKO
- RIGL
- Stock Information
- Founded
- ARKO 1970
- RIGL 1996
- Country
- ARKO United States
- RIGL United States
- Employees
- ARKO N/A
- RIGL N/A
- Industry
- ARKO Oil Refining/Marketing
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- ARKO Energy
- RIGL Health Care
- Exchange
- ARKO Nasdaq
- RIGL Nasdaq
- Market Cap
- ARKO 453.2M
- RIGL 537.6M
- IPO Year
- ARKO N/A
- RIGL 2000
- Fundamental
- Price
- ARKO $4.36
- RIGL $42.26
- Analyst Decision
- ARKO Buy
- RIGL Buy
- Analyst Count
- ARKO 3
- RIGL 6
- Target Price
- ARKO $7.50
- RIGL $39.83
- AVG Volume (30 Days)
- ARKO 433.5K
- RIGL 652.5K
- Earning Date
- ARKO 11-05-2025
- RIGL 11-04-2025
- Dividend Yield
- ARKO 2.75%
- RIGL N/A
- EPS Growth
- ARKO N/A
- RIGL 2698.26
- EPS
- ARKO 0.11
- RIGL 6.20
- Revenue
- ARKO $7,887,822,000.00
- RIGL $282,076,000.00
- Revenue This Year
- ARKO N/A
- RIGL $59.93
- Revenue Next Year
- ARKO N/A
- RIGL N/A
- P/E Ratio
- ARKO $40.09
- RIGL $6.77
- Revenue Growth
- ARKO N/A
- RIGL 79.13
- 52 Week Low
- ARKO $3.51
- RIGL $14.63
- 52 Week High
- ARKO $7.84
- RIGL $43.72
- Technical
- Relative Strength Index (RSI)
- ARKO 49.69
- RIGL 71.17
- Support Level
- ARKO $4.26
- RIGL $34.00
- Resistance Level
- ARKO $4.48
- RIGL $39.56
- Average True Range (ATR)
- ARKO 0.19
- RIGL 2.32
- MACD
- ARKO 0.01
- RIGL 1.15
- Stochastic Oscillator
- ARKO 68.33
- RIGL 97.43
About ARKO ARKO Corp.
ARKO Corp owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in four segments: Retail segment, Wholesale segment, fleet fueling segment, and GPM Petroleum segment. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.